Flu surges across U.S. as doctor visits reach highest level since 1997

CDC surveillance through Dec. 27 shows at least 11 million flu cases, roughly 120,000 hospitalizations and 5,000 deaths, with 8.2% of outpatient visits for influenza-like illness—the highest level since 1997—and 48 jurisdictions at high or very high activity. H3N2 is dominant among subtyped influenza (91.2% of subtyped specimens), about 130 million vaccine doses have been administered but uptake is lower than prior seasons, and the CDC’s updated childhood vaccine guidance recommending shared clinical decision-making has drawn criticism from major medical societies. The surge raises near-term downside risk to workforce availability, hospital capacity and payer costs and could affect healthcare providers, hospitals, insurers and vaccine-related equities while prompting policy and public-health debate.

Analysis

Market structure: Acute H3N2-driven spike disproportionately favors makers/distributors of vaccines, antivirals and diagnostics (Pfizer PFE, Moderna MRNA, Abbott ABT, Roche/RHHBY exposure) and retail pharmacies (CVS, WBA, WMT) via higher foot traffic and product sales; hospitals (HCA, UHS) see revenue per patient rise but margin pressure from capacity and staffing costs. Consumer discretionary and travel (AAL, DAL, RCL) are near-term losers from absenteeism and Cancelled trips; pricing power will be strongest for scarce antivirals/rapid tests and weakest for elective services and leisure bookings.

Risk assessment: Tail risks include a vaccine-mismatch or extended H3N2 season leading to sustained hospital strain and possible government bulk purchases or price negotiation — low probability but high impact on manufacturer revenues and supply chains over 1–6 months. Time horizons: immediate (days–weeks) for diagnostic/OTC demand spikes; short-term (1–3 months) for hospital/insurer claim flow and retail earnings; long-term (3–12 months) for vaccine uptake trends, inventory cycles and regulatory fallout from pediatric schedule changes. Hidden dependencies include school attendance, corporate sick‑leave policies, and antiviral manufacturing capacity.

Trade implications: Favor concentrated, sized, and timed exposure: go long 2–3% positions in PFE and ABT to play vaccine/diagnostics demand through Q1–Q2 2026; buy 1–2% long positions in CVS or WMT for incremental OTC/test sales (hold 4–12 weeks). Hedge or short 1–2% in airlines/cruise operators (AAL, RCL) via put spreads for the next 4–8 weeks; use call spreads on PFE/MRNA with 3–6 month expiries to limit drawdown and put spreads on AAL 1–2 month expiries to monetize near-term travel weakness.

Contrarian angles: Consensus assumes durable upside for vaccine makers — but lower overall vaccination rates (only ~130M doses YTD) and potential seasonal moderation suggest upside is capped and inventory risk exists into H2/2026. Historical precedent (2017–18 H3N2) shows diagnostics and retail benefit early while pharmaceutical uplift is modest and concentrated; if CDC pediatric guidance reduces routine shots, expect legal/regulatory noise and polarized demand that can create asymmetric risk for small-cap supply players and overstock losses at large manufacturers.

Key Decisions for Investors

• Establish a 2–3% long position in Pfizer (PFE) using a 3–6 month call spread (buy 1–2% notional 10–15% OTM call, sell slightly higher strike) to capture vaccine and antiviral demand into Q2 2026; increase to 4% if CDC outpatient flu visits remain >=8% for two consecutive weeks.
• Allocate 1–2% long to Abbott Laboratories (ABT) outright shares to play diagnostic/rapid-test surge, target exit 4–8 weeks or on ABT relative outperformance vs XLV by +3%.
• Establish a 1–2% long in CVS Health (CVS) or Walmart (WMT) to capture OTC/clinic demand; tactically harvest gains in 4–12 weeks or if same‑store sales miss by >200bps.
• Open a 1–2% short via put spreads on airlines (American AAL 1–2 month put spread) or cruise (RCL 1–2 month put spread) to hedge travel exposure; widen size if CDC reports school closures or hospitalization growth >10% week-over-week.
• Monitor two triggers closely for further action: (a) CDC ILINet outpatient visits staying >=8% for three consecutive weeks — add to long diagnostics/vaccine positions; (b) national vaccine doses administered crossing 150M — tighten stops on vaccine longs and consider partial profit taking within 30 days.